Big Take15 Feb 2023

Thousands Claim A Blockbuster Drug Gave Them Cancer

In 2020, the enormously popular heartburn medication Zantac was pulled from store shelves after samples were found to contain the probable carcinogen NDMA.

The drug has since been re-introduced with a new formula that is considered safe to use as directed.

But tens of thousands of people who took the old version of the drug, made with the active ingredient ranitidine, are now suing Zantac’s maker, then called Glaxo and now known as GSK. They claim the medication gave them cancer and are seeking compensation. The company is pushing back, saying there is no conclusive evidence or scientific consensus that ranitidine can degrade and form NDMA in harmful amounts under normal conditions.

Reporters Anna Edney, Susan Berfield, and Jef Feeley dug into the claims and counterclaims for Bloomberg Businessweek, and they join this episode to talk about Zantac’s rise and fall and where these lawsuits are headed.

And Dr. Jaap Venema, chief science officer at US Pharmacopeia, explains how potential carcinogens get into drugs–and what pharmaceutical companies and government agencies are–and should be–doing to ensure the safety of the medications we take.

Read the story: https://bloom.bg/3Yxzno2

Listen to The Big Take podcast every weekday and subscribe to our daily newsletter: https://bloom.bg/3F3EJAK

Have questions or comments for Wes and the team? Reach us at bigtake@bloomberg.net.

See omnystudio.com/listener for privacy information.

Denne episoden er hentet fra en åpen RSS-feed og er ikke publisert av Podme. Den kan derfor inneholde annonser.

Episoder(1012)

Could Bond Yields Break the Stock Market?

At over 5%, the 10-year Treasury yield is the highest since 2007. Those soaring yields are raising lots of questions about whether investors should be trimming stocks and buying bonds. But timing such...

28 Sep 17min

Weekend Listen: There's a Mind-Boggling Number of Rich People in America

In 2014, the economists Owen Zidar and Eric Zwick were asked by the US Treasury to conduct a study on the tax burden of private business owners. One of their central findings is that there are about t...

27 Sep 59min

Crafting America’s Favorite Countertops Is Killing Workers

People who fabricate artificial stone are getting sick with a deadly chronic illness—on that, there’s no debate. But whether it’s the individual shops or the material’s manufacturers who should be hel...

25 Sep 21min

This Isn’t Your Grandparents’ UN

At this week’s UN General Assembly meeting in New York, an AI executive delivered dire warnings via video. President Trump threatened to annihilate Iran. China’s Xi Jinping skipped the meeting altoget...

24 Sep 15min

Why Everyone Is Talking About High Diesel Prices

Diesel prices are hitting new highs, and voters aren’t happy. With the midterms approaching, the Trump administration is trying to find ways to curb fuel costs, including a potential US diesel export ...

23 Sep 17min

US-China AI Race to Take Center Stage at Trump-Xi Meeting

As Chinese President Xi Jinping makes his first visit to Washington in over a decade, trade and the AI race will likely dominate talks with Donald Trump. On today’s Big Take Asia podcast, host K. Oanh...

22 Sep 16min

How Much Is the Hormuz Blockade Costing the US?

The Iran War is likely to take center stage when President Trump meets with Gulf leaders on the sidelines of this week's UN General Assembly. Houthi attacks in Saudi Arabia and rising energy prices un...

21 Sep 14min

Big Pharma Needs New Drugs. China Has Them

American pharma giants are increasingly turning to Chinese labs to discover, test and develop cutting-edge drugs. On the Big Take Asia podcast, Bloomberg’s Amber Tong and Robert Langreth join Oanh Ha ...

20 Sep 17min